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type 1 diabetes: a 6-year post-trial follow-up
Peter R van Dijk1*, Susan JJ Logtenberg1,2, Klaas H Groenier1,3, Rijk OB Gans2, Nanne Kleefstra1,2,4 and Henk JG Bilo1,2,5Abstract
Background: Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump is a treatment option for
patients with type 1 diabetes mellitus (T1DM). Aim of the present study was to describe the long-term course of
glycaemic control, complications, health related quality of life (HRQOL) and treatment satisfaction among T1DM
patients treated with CIPII.
Methods: Nineteen patients that participated in a randomized cross-over trial comparing CIPII and subcutaneous
(SC) therapy in 2006 were followed until 2012. Laboratory, continuous glucose monitoring, HRQOL and treatment
satisfaction measurements were performed at the start of the study, the end of the SC-, the end of the CIPII
treatment phase in 2006 and during CIPII therapy in 2012. Linear mixed models were used to calculate estimated
values and to test differences between the moments in time.
Results: In 2012, more time was spent in hyperglycaemia than after the CIPII treatment phase in 2006: 37%
(95% CI 29, 44) vs. 55% (95% CI 48, 63), mean difference 19.8% (95% CI 3.0, 36.6). HbA1c was 65 mmol/mol
(95% CI 60, 71) at the end of the SC treatment phase in 2006, 58 mmol/mol (95% CI 53, 64) at the end of the
CIPII treatment phase and 65 mmol/mol (95% CI 60, 71) in 2012, respectively (p > 0.05). In 2012, the median
number of grade 2 hypoglycaemic events per week (1 (95% CI 0, 2)) was still significantly lower than during prior
SC therapy (3 (95% CI 2, 4)): mean change −1.8 (95% CI −3.4, −0.4). Treatment satisfaction with CIPII was better
than with SC insulin therapy and HRQOL remained stable. Pump or catheter dysfunction of the necessitated
re-operation in 7 patients. No mortality was reported.
Conclusions: After 6 years of CIPII treatment, glycaemic regulation is stable and the number of hypoglycaemic
events decreased compared to SC insulin therapy. Treatment satisfaction with CIPII is superior to SC insulin therapy,
HRQOL is stable and complications are scarce. CIPII is a safe and effective treatment option for selected patients
with T1DM, also on longer term.
Keywords: Type 1 diabetes mellitus, Intraperitoneal insulin, Insulin infusion devices, Quality of life, Treatment satisfaction,
Complications, Subcutaneous insulinBackground
The mainstay of type 1 diabetes mellitus (T1DM) treat-
ment consists of subcutaneous (SC) insulin administration
using multiple daily injections (MDI) or continuous sub-
cutaneous insulin infusion (CSII) with an externally placed
pump. Although most patients achieve acceptable glycae-
mic control using MDI or CSII, a relatively small group of
patients fails to reach adequate glycaemic control, have
frequent hypoglycaemic episodes or SC insulin resistance,* Correspondence: P.r.van.dijk@isala.nl
1Diabetes Centre, Isala, P.O. box 10400, 8000G.K Zwolle, The Netherlands
Full list of author information is available at the end of the article
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unless otherwise stated.despite intensive SC insulin therapy. For these patients,
continuous intraperitoneal insulin infusion (CIPII) with an
implantable pump is a treatment option [1].
With intraperitoneal administration, insulin is better
absorbed and allows blood glucose levels to return to
baseline values more rapidly with more predictable insulin
profiles compared to SC insulin administration [2,3]. The
higher hepatic uptake of insulin mitigates peripheral
plasma insulin concentrations compared to SC adminis-
tration [3,4]. Other possible effects include improvement
of the impaired glucagon and hepatic glucose productionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ipheral hyperinsulinaemia [5].
In 2006, a randomized, cross-over study was perfor-
med at our centre to investigate the effects of CIPII on
the risk of hypoglycaemia, compared to intensive SC in-
sulin treatment, both for a six-month period. Glycaemic
control, health related quality of life (HRQOL) and treat-
ment satisfaction improved during CIPII treatment as
compared to SC insulin administration and there was no
reduction or increase in hypoglycaemic events [6,7].
After the study all participants chose to continue CIPII.
Aim of the current analysis is to investigate long-term
glycaemic control, HRQOL, treatment satisfaction and com-
plications among patients with T1DM, treated with CIPII.
Methods
Study population
Twenty three patients with T1DM, low fasting C-peptide
concentrations (<0.20 nmol/l) and intermediate or poor
glycaemic control, defined as HbA1c ≥58 mmol/mol
and/or ≥5 incidents of hypoglycaemia (<4.0 mmol/l) per
week, who were aged 18–70 years and treated with SC
insulin, were included in the cross-over study in 2006.
The exclusion criteria were: impaired renal function
(plasma creatinine ≥150 μmol/L or glomerular filtration
rate ≤50 ml/min), cardiac problems (unstable angina or
myocardial infarction within the previous 12 months or
New York Heart Association class III or IV congestive
heart failure), mentally handicapped, current or past psy-
chiatric treatment for schizophrenia, cognitive or bipolar
disorder, current use or oral corticosteroids or suffering
from a condition which necessitated oral or systemic
corticosteroids use more than once in the previous
12 months, substance abuse, other than nicotine, current
pregnancy or plans to become pregnant during the trial,
plans to engage in activities that require going >25 feet
below sea level. After the cross-over study all patients
chose to continue CIPII with an implantable pump
(Minimed Insulin Pump).
Study design
The previous study (NCT00286962) started in 2006, had
an open-label, randomized cross-over design and was
performed at Isala (Zwolle, the Netherlands). The study
consisted of 4 phases: the qualification phase, the first
treatment phase, the crossover phase, and the second
treatment phase. After a 3-month qualification phase,
patients were randomly allocated to one of two groups,
which differed only in the sequence of the two therapies.
Between both treatment phases of 6 months, a crossover
phase of 4 weeks was instituted to minimize the carry-
over effects of CIPII. The results of this study were
reported previously and showed a significant decrease in
HbA1c, with more time spent in euglycaemia andwithout a change in hypoglycaemic events with CIPII as
compared to SC insulin therapy. In addition, HRQOL
and treatment satisfaction improved with CIPII. [6,7].
Follow-up measurements for the present analysis were
performed in December 2012 until March 2013.
Procedures and methods
At the start of the 2006 cross-over study, 3 patients were
on MDI and 20 on CSII. During the SC treatment phase
in the 2006 study, SC insulin was delivered with either
MDI or CSII, according to what was used prior to the
study. Patients treated with MDI continued to use their
own insulin regime, i.e. rapid acting insulin analogues
before meals and a daily dose of long acting insulin.
Patients treated with CSII used rapid acting insulin ana-
logues. During the crossover phase insulin was admi-
nistered SC. If the subject was using more than 40 IU of
SC insulin per day prior to starting the CIPII phase of
the study, his or her starting dose was set at 90% of the
prior SC dose. Subjects using less than 40 IU of SC insu-
lin received a starting dose of 80% of the prior SC dose.
Initially the dose was equally divided between a basal
rate (50%) and a bolus before meals [8].
In 2006–2007, the CIPII pump was implanted under
general anaesthesia at the start of the CIPII phase in all
subjects. Insulin (U-400 HOE 21PH, semi synthetic human
insulin of porcine origin, trade name: Insuplant® Hoechst,
Frankfurt, Germany, nowadays Sanofi-Aventis) was admin-
istered with the implantable pump. Since there were no
batches left of the U400 semi synthetic human insulin, a
new human recombinant insulin (400 IU/ml; human insu-
lin of E. Coli origin, trade name: Insuman Implantable®,
Sanofi-Aventis) was used from 2010 onwards. Between
2006 and 2012, all patients received standard care at our
outpatient clinic which consisted of insulin refills every
6–12 weeks and an rinse procedure with NaOH was
performed every 9 months or in case of insulin underde-
livery. The insulin pump, implantation, insulin dosage
and refill procedures have been described in more detail
previously [9,8]. An illustration of the implantable pump
is provided in Figure 1.
Measurements
In order to yield information about the long-term
impact of CIPII on glycaemic control in comparison to
that on SC insulin therapy, we compared data derived
from the measurements in 2012/2013 with data from
the start of the 2006 study, the end of the SC-, the end of
the CIPII phase of the 2006 cross-over study.
Demographic and clinical parameters included smoking
and alcohol habits, year of diagnosis of diabetes, presence
of complications, any comorbidity, height and weight,
daily insulin dose, number of self-reported hypoglycaemic
events grade 1 (<4.0 mmol/L) and grade 2 (<3.5 mmol/L)
Figure 1 Legend: Illustration of the implantable pump in situ (derived from [9]).
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with a Primus Ultra2 system using high-performance
liquid chromatography (reference value 20–42 mmol/mol).
In addition, 5- to 7-day 24-hours interstitial glucose pro-
files were recorded with a continuous glucose monitoring
(CGM) system (iPro2, Medtronic, Northridge, CA, USA).
Time spent in the hypoglycaemic range was defined as the
percentage of CGM recordings <4.0 mmol/L, time spent in
euglycaemic range was defined as the percentage of CGM
recordings from 4.0 to 10.0 mmol/L, and time spent
in hyperglycaemic range was defined as the percentage of
CGM recordings >10.0 mmol/L.
For HRQOL assessment, the 36-item short-form health
survey (SF-36) and the World Health Organization-Five
Well-Being Index (WHO-5) questionnaires were used. The
SF-36 is a widely used, generic questionnaire with 36 items
involving eight subscales and a physical and mental compo-
nent summary (PCS and MCS, respectively). Scale scores
range from 0–100, with higher scores indicating better
HRQOL [10,11]. The WHO-5 is designed to measure posi-
tive well-being and is reported to be better in identifying
depression than the MCS [12,13]. It consists of five items
with a total score ranging from 0–100. A total score below
50 or answer of ’0 or 1’ suggests poor emotional well-being
[14]. Treatment satisfaction was measured with the Diabetes
Treatment Satisfaction Questionnaire (DTSQs). All eight
items are scored on a 7-point scale. Two items assess per-
ceived frequency of hyperglycaemia and hypoglycaemia, and
six items comprise the treatment satisfaction scale, with
higher scores indicating higher satisfaction (range 0–36) [15].Statistical analysis
Descriptive summaries included the mean with standard
deviation (SD) for normally distributed variables and the
median with the interquartile range (25th-75th percentile)
for other variables. Q-Q plots were used to determine if the
tested variable had a normal distribution or not. Time vari-
ables, such as times spent in the different glycaemic states,
are presented as absolute values. Linear mixed models with
Bonferroni correction were used to calculate and to test dif-
ferences in time. Estimated values and estimated differ-
ences, calculated with linear mixed models, are reported.
All observed values are presented in Additional file 1.
All statistical analysis were performed with SPSS software
(version 20.0, Inc, Chicago, Il, USA). A two-sided signifi-
cance level of 0.05 was considered statistically significant.
Ethical considerations
Studies were performed in accordance with the Declar-
ation of Helsinki. For this study, informed consent was
obtained from all patients in 2006 as well as in 2012.
Approval by the medical ethics committee of the Isala
(Zwolle, The Netherlands) was given for the crossover
study in 2006 and the follow-up measurements in 2012.
Results
Patients
Of 23 patients who participated in the previous cross-
over study, 22 were still treated with CIPII in 2012. One
patient stopped CIPII treatment due to neuropathic
pains. The patient believed the implanted pump caused
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current analysis: 1 due to chronic prednisolone use for
myasthenia gravis and 1 due to participation in an in vitro
fertilization program. One patient refused participation.
Therefore, 19 patients (53% male) are included in the
present analysis, with a mean age of 45 (10) years and a
diabetes duration 23 (16, 33) years at the start of the 2006
study. Four of these patients are current smokers.
Clinical parameters
The estimated values of the clinical parameters and com-
parisons between the start of the 2006 study, the end of
the SC-, the end of the CIPII treatment phase and the start
of the present 2012 study, 6 (0.4) years later, are presented
in Table 1. Systolic blood pressure, BMI, cholesterol and
the insulin dose remained stable over time. Two patients
were diagnosed with neuropathy, one with retinopathy and
one with a macrovascular complication (occlusion of the
femoral artery). There were no new cases of nephropathy.
Glycaemic parameters
As shown in Table 1, the mean estimated HbA1c in 2012
was 65 (95% confidence interval (CI) 60, 71) mmol/mol and
was not significantly different from the HbA1c at the start
of the 2006 study: 70 (95% CI 64, 75) mmol/mol, with a










SBP (mmHg) 141 (133, 150) 135 (126, 143) 139 (130, 147) 14
BMI (kg/m2) 26 (24, 29) 27 (24, 29) 28 (25, 30) 26
Total cholesterol 4.8 (4.5, 5.2) 4.7 (4.3, 5.1) 4.5 (4.1, 4.9) 4.8
HDL cholesterol 1.8 (1.6, 2.0) 1.8 (1.5, 2.0) 1.6 (1.3, 1.8) 1.7
LDL cholesterol 2.6 (2.3, 3.0) 2.5 (2.2, 2.8) 2.4 (2.1, 2.7) 2.8
Triglycerides 0.9 (0.7, 1.2) 1.1 (0.8, 1.3) 1.3 (1.0, 1.5) 1.0
Total insulin dose (IU/day) 19 (13, 24) 25 (20, 31) 20 (15, 25) 20
Basal insulin dose (IU/day) 35 (24, 45) 32 (22, 43) 35 (25, 46) 44
Bolus insulin dose (IU/day) 54 (40, 67) 58 (44, 71) 56 (42, 69) 65
Glycaemic parameters
HbA1c (mmol/mol) 70 (64, 75) 65 (60, 71) 58 (53, 64) 65
Hypoglycaemia grade 1 † 4 (3, 6) 4 (3, 6) 4 (2, 5) 3 (
Hypoglycaemia grade 2 ‡ 3 (2, 4) 3 (2, 4) 2 (2, 3) 1 (
Time spent in
hypoglycaemia (%)
8 (5, 11) 8 (5, 11) 6 (3, 9) 5 (
Time spent in
hyperglycaemia (%)
45 (36, 54) 47 (38, 56) 39 (30, 48) 59
Time spent in
euglycaemia (%)
47 (39, 54) 45 (38, 53) 55 (48, 63) 37
Estimated values and differences are reported. Data are presented as estimated me
rounding. BMI; Body Mass Index, CIPII; continuous intraperitoneal insulin infusion, S
number of blood glucose values <4.0 mmol/L per week. ‡ Defined as the number o5.9; p = 1.0). Although there was a tendency to rise, the
HbA1c in 2012 did not differ significantly from the HbA1c
at the end of the SC phase (−0.1 mmol/mol 95% CI −10.5,
10.3; p = 1.0) and the end of the CIPII phase (7.1 mmol/mol
95% CI −3.3, 17.5; p = 0.4) of the 2006 study.
The number of grade 2 hypoglycaemic events per
week decreased from 3 (95% CI 2, 4), at the start and at
the end of the SC therapy phase of the 2006 study, to 1
(95% CI 0, 2) event per week in 2012. In 2012, compared
with the start of the 2006 study the mean change was −1.8
events per week (95% CI −3.4,-0.4; p = 0.008) and compared
with the end of SC therapy phase the mean change
was −1.9 (95% CI −3.5, −0.4; p = 0.007). More time was
spent in hyperglycaemia during CGM measurements in
2012 than at the end of the CIPII phase in 2006: mean
change 19.8 (95% CI 3.0, 36.6; p = 0.013). Percentage time
spent in euglycaemia with CIPII in 2012 was less than at
the end of the CIPII phase of the 2006 study: mean
change −18.7% (95% CI −33.3, −4.1; p = 0.005).
HRQOL and Treatment satisfaction
As shown in Table 2, none of the SF-36 subscales and
summary scores changed over time. The WHO-5 scores
in 2012 remained stable over the years with CIPII. In
2012, 8 patients had a poor emotional well-being accord-
ing to the WHO-5, compared to 9 at the end of the SC12
dy (D)
D vs. A D vs. B D vs. C
0 (131, 149) −1. -1.1 (−17.6, 15.5) 5.5 (−11.0, 22.0) 1.3 (−15.2, 17.9)
(24, 29) −0.4 (−4.9, 4.1) −0.2 (−5.3, 4.9) −1.2 (−6.1, 3.7)
(4.4, 5.2) −0.1 (−0.9, 0.7) 0.0 (−0.7, 0.8) −0.2 (−0.5, 1.0)
(1.4, 1.9) −0.1 (−0.6, 0.3) −0.1 (−0.6, 0.4) 0.1 (−0.3, 0.6)
(2.5, 3.1) 0.2 (−0.4, 0.8) 0.3 (−0.3, 0.9) 0.4 (−0.2, 1.1)
(0.7, 1.3) −0.1 (−0.5, 0.6) −0.1 (−0.6, 0.5) −0.3 (−0.8, 0.3)
(15, 26) 8.2 (−18.3, 34.7) 8.2 (−17.6, 33.9) 6.1 (−19.7, 31.8)
(34, 55) 9.6 (−10.6, 29.8) 12.0 (−8.1, 32.2) 8.5 (−11.7, 28.7)
(51, 78) 1.4 (−8.9, 11.7) −5.1 (−15.3, 5.2) 0.4 (−9.9, 10.7)
(60, 71) −4.5 (−14.9, 5.9) −0.1 (−10.5,10.3) 7.1 (−3.3, 17.5)
1, 4) −1.8 (−4.2, 0.7) −1.7 (−4.2, 0.8) −1.1 (−3.6, 1.4)
0, 2) −1.8 (−3.4,-0.4)* −1.9 (−3.5, −0.4)* −1.4 (−3.0, 0.1)
2, 7) −3.7 (−9.3, 1.9) −3.6 (−9.2, 2.0) −1.1 (−6.7, 4.5)
(50, 68) 13.7 (−3.1, 30.5) 12.0 (−4.8, 28.8) 19.8 (3.0, 36.6)*
(29, 44) −10.0 (−24.6, 4.6) −8.4 (−23.0, 6.2) −18.7 (−33.3, −4.1)*
an (95% CI) or mean change (95% CI). Numbers may not add up due to
BP; systolic blood pressure, SC; subcutaneous. *p < 0.05. † Defined as the
f blood glucose values <3.5 mmol/L per week.









D vs. A D vs. B D vs. C
SF-36 subscales
Physical functioning 76 (66, 86) 69 (59, 79) 81 (71, 91) 76 (65, 86) −0.3 (−19.7, 19.1) 7.4 (−12.1, 26.8) −5.3 (−24.7, 14.1)
Social functioning 68 (53, 76) 65 (53, 76) 77 (66, 88) 74 (63, 85) 6.6 (−14.7, 27.8) 9.9 (−11.4, 31.2) −2.6 (−32.9, 18.6)
Role limitations-physical 38 (17, 59) 42 (21, 63) 66 (45, 87) 57 (36, 78) 18.4 (−22.0, 58.8) 14.5 (−26.0, 54.9) −9.2 (−49.6, 31.2)
Role limitations-emotional 68 (50, 87) 68 (50, 87) 86 (67, 100) 77 (58, 96) 8.8 (−27.3, 44.8) 8.8 (−27.3, 44.8) −8.8 (−44.8, 27.3)
Mental health 70 (60, 79) 67 (58, 77) 77 (68, 87) 79 (70, 89) 9.6 (−8.1, 27.4) 12.0 (−5.8, 29.7) 2.1 (−15.7, 19.8)
Vitality 48 (39, 58) 43 (34, 71) 62 (52, 71) 58 (49, 67) 9.5 (−7.9, 26.9) 15.3 (−2.2, 32.7) −4.5 (−32.9, 12.8)
Bodily pain 64 (52, 75) 64 (53, 76) 66 (54, 77) 67 (56, 78) 3.3 (−18.5, 25.0) 2.6 (−19.2, 24.3) 1.4 (−20.4, 23.1)
General health 41 (32, 50) 46 (37, 54) 56 (47, 64) 48 (38, 56) 6.5 (−10.1, 23.1) 1.7 (−14.9, 18.3) −8.0 (−24.7, 8.6)
SF-36 summary scores
Physical component score 56 (46, 65) 55 (45, 64) 68 (58, 77) 63 (54, 73) 7.3 (−10.9, 25.6) 8.5 (−9.7, 26.8) −4.7 (−23.0, 13.5)
Mental component score 59 (50, 68) 58 (49, 67) 72 (63, 81) 67 (58, 76) 8.2 (−9.1, 25.5) 9.5 (−7.7, 26.8) −4.4 (−21.6, 12.9)
WHO-5 score 49 (39, 59) 47 (37, 57) 69 (59, 79) 60 (50, 70) 10.5 (−9.0, 30.0) 12.6 (−6.9, 32.1) −9.2 (−28.8, 10.2)
DTSQ
Total score 24 (21, 27) 24 (21, 27) 33 (30, 36) 33 (29, 36) 8.3 (2.3, 14.3)* 8.4 (2.4,14.3)* −0.3 (−6.3, 5.7)
Perceived hypoglycaemia score 5 (4, 6) 5 (4, 5) 2 (2, 3) 4 (3, 5) −0.4 (−2.0, 1.2) −0.8 (−2.4, 0.8) 0.3 (−1.3, 1.9)
Perceived hyperglycaemia score 3 (2, 4) 4 (3, 5) 3 (2, 3) 3 (2, 4) −1.1 (−2.4, 0.1) −0.9 (−2.1, 0.3) 1.5 (0.2, 2.7)*
Estimated values and differences are reported. Data are presented as estimated mean (95% CI) or mean change (95% CI). Numbers may not add up due to
rounding. DTSQ; Diabetes Treatment Satisfaction Questionnaire, CIPII; continuous intraperitoneal insulin infusion, SC; subcutaneous, SF-36; 36-item short-form
health survey, WHO-5; World Health Organization-Five Well-Being Index *p < 0.05.
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ment satisfaction remained significantly higher with CIPII
than with SC insulin: the mean difference between 2012
and the start of the 2006 study was 8.3 (95% CI 2.3, 14.3;
p = 0.001) and between 2012 and the end of the SC phase
was 8.4 (95% CI 2.4, 14.3; p = 0.001). The perceived hyper-
glycaemia score of the DTSQ was higher in 2012 than at
the end of the 2006 CIPII therapy phase: 1.5 (95% CI 0.2,
2.7; p = 0.01).
Device complications
After a mean duration of 5 (1.0) years, 3 cases of pump
dysfunction and 3 cases of (expected) battery end-of-life
necessitated replacement of the pump. In 3 patients a
laparoscopic procedure was performed to replace the
catheter and in 1 patient a laparoscopic operation was
necessary to remove a fibrin plug from the tip of the
catheter. The mean duration of hospital admission for
the 10 patients who experienced any pump related
issue (including planned replacement due to battery
end-of-life) was 0.6 (0, 1) days per year. No mortality
was reported.
Discussion
After 6 years of treatment with CIPII, HbA1c leveled
with the value these T1DM patients had during intensive
SC therapy, prior to starting CIPII. Nevertheless, patients
experienced significant less grade 2 hypoglycaemic eventsand remained much more satisfied with CIPII compared
to the SC treatment.
During the previous cross-over trial in which CIPII
was commenced there was a significant decrease in
HbA1c compared to the SC treatment phase from 70 to
58 mmol/mol. Compared to the SC treatment phase, the
decrease in that study was significantly greater with
CIPII with a mean difference of 8.4 mmol/mol. During
the follow-up period described in the present study
HbA1c stabilized at a level of 65 mmol/mol, which was
not different to the levels prior and shortly after starting
CIPII 6 years before. Several studies have described the
effect of CIPII, as compared to SC insulin therapy, on
glycaemic control. In all 3 short-term randomized stud-
ies, HbA1c improved with CIPII [6,16,17]. In contrast to
the findings in the present study, HbA1c improvement
persisted over the years in subsequent long-term ob-
servational studies. Nevertheless, follow-up duration
(45 days to 7.3 years) varied substantially between studies
and, importantly, not all patients in those studies had
intermediately or poorly controlled T1DM (HbA1c 63 to
83 mmol/mol) [18-24].
In line with previous studies, the number of grade 2
hypoglycaemic events decreased during CIPII in the
present cohort as compared to prior SC therapy [16,20,25].
This may well be the result of a slightly more hypergly-
caemic profile. Although speculative, the restoration of the
portal to peripheral insulin gradient with CIPII treatment,
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production in response to hypoglycaemia, may also help to
explain this finding [5,26].
The HbA1c course in the current cohort may be partly
explained by the effect of being under strict study condi-
tions during the cross-over study, which diminishes after
the end of the study. Several other explanations may be
taken into account. First, complications of CIPII may
also have a negative influence on glycaemic regulation.
Second, it should be mentioned that from 2010 onwards
all CIPII patients switched to another insulin (Insuman®
Implantable 400 IU/mL) because the previous insulin
batch (U-400 HOE 21PH, Insuplant® 400 IU/mL) was no
longer available. The effect of the change in insulin for-
mulation remains to be determined from an on-going
study (clinical trials identifier NCT01194882).
The switch from SC insulin to CIPII increases HRQOL,
which stabilizes over time [7,20]. In the present study the
level of HRQOL among CIPII treated subjects perpetu-
ated. Nevertheless, as found in other studies and under-
lined by the fact that 42% of all patients had a WHO-5
score indicating poor emotional well-being, the HRQOL
of these individuals remains poor [1,19,20]. We found the
SF-36 subscales role-physical and vitality to be comparable
to patients with a minor (uncomplicated) chronic disease
and the other subscales similar to patients with compli-
cated diabetes or complicated coronary artery disease [27].
Still, it is likely that the short duration of hospital admis-
sions found in the present study, compared to 45 days per
year before implantation of the pump previously described
in a similar population, positively influence HRQOL and
treatment satisfaction [19].
Since CIPII is used as a last treatment option in the
Netherlands, the population in the present study is com-
plex, strictly selected, and has a small size. On the other
hand this limitation reflects general practice nowadays
where CIPII is limited to a small number of patients in a
small number of centers. Furthermore, when interpreting
the comparisons between CIPII and previous SC therapy
made in this study one should take differences in treat-
ment periods (e.g. a duration of 6 months of the SC phase
during a controlled study versus 6.4 years of subsequent
CIPII therapy) into account. Prospective, long-term and
large-scale studies with respect to i.e. glycaemic control,
HRQOL and cost-effectiveness to compare SC and CIPII
therapy for T1DM are imperative.
Conclusions
Taken together, the stable HRQOL, increased treatment
satisfaction, little time spent in hospital and stable HbA1c
combined with a decrease in grade 2 hypoglycaemic
events as compared to previous SC therapy underlines the
clinical observation that CIPII is a valuable treatment op-
tion for selected patients with T1DM, also on longer term.Additional file
Additional file 1: Observed values at the different moments in time.
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